Skip to main content
. 2020 Jun 10;11:534. doi: 10.3389/fneur.2020.00534

Figure 2.

Figure 2

Proportion of HOPR stratified by dual antiplatelet therapy and CYP2C19 loss-of-function allele carrier status at baseline, 7 + 2 days and 90 ± 7 days. HOPR indicates high on-treatment platelet reactivity; AA, arachidonic acid; ADP, adenosine diphosphate.